Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 12
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Acute leukemia in early childhood BJMBR
Emerenciano,M.; Koifman,S.; Pombo-de-Oliveira,M.S..
Acute leukemia in early childhood is biologically and clinically distinct. The particular characteristics of this malignancy diagnosed during the first months of life have provided remarkable insights into the etiology of the disease. The pro-B, CD10 negative immunophenotype is typically found in infant acute leukemia, and the most common genetic alterations are the rearrangements of the MLL gene. In addition, the TEL/AML1 fusion gene is most frequently found in children older than 24 months. A molecular study on a Brazilian cohort (age range 0-23 months) has detected TEL/AML1+ve (N = 9), E2A/PBX1+ve (N = 4), PML/RARA+ve (N = 4), and AML1/ETO+ve (N = 2) cases. Undoubtedly, the great majority of genetic events occurring in these patients arise prenatally....
Tipo: Info:eu-repo/semantics/article Palavras-chave: Infant acute leukemia; MLL; Acute lymphoblastic leukemia; Acute myeloid leukemia; Maternal exposures; Molecular and exploratory epidemiology.
Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000600002
Imagem não selecionada

Imprime registro no formato completo
Acute leukemias in Piauí: comparison with features observed in other regions of Brazil BJMBR
Rego,M.F.N.; Pinheiro,G.S.; Metze,K.; Lorand-Metze,I..
Differences in age and sex distribution as well as FAB (French-American-British classification) types have been reported for acute leukemias in several countries. We studied the demographics and response to treatment of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) between 1989 and 2000 in Teresina, Piauí, and compared these results with reports from Brazil and other countries. Complete data concerning 345 patients (230 ALL, 115 AML) were reviewed. AML occurred predominantly in adults (77%), with a median age of 34 years, similar to that found in the southeast of Brazil but lower than the median age in the United States and Europe (52 years). FAB distribution was similar in children and adults and FAB-M2 was the most...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute lymphoblastic leukemia; Acute myeloid leukemia; Epidemiology.
Ano: 2003 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000300007
Imagem não selecionada

Imprime registro no formato completo
Acute myeloid leukemia in elderly patients: experience of a single center BJMBR
Rodrigues,C.A.; Chauffaille,M.L.L.F.; Pelloso,L.A.F.; Ghaname,F.S.; Kerbauy,D.M.B.; Campos,M.G.V.; Yamamoto,M..
Acute myeloid leukemia (AML) is a disease predominantly of older adults. Treatment of AML in the elderly is complicated not only by comorbidities but also by the high prevalence of poor prognosis markers. Thirty-one consecutive unselected patients with AML older than 60 years (representing 33% of all AML cases diagnosed at our institution during the same period) were followed over a period of 5 years (1997-2002). A high incidence of AML with multilineage dysplasia (45%) and no favorable cytogenetic abnormalities but 62% intermediate and 38% unfavorable karyotypes were found. Sixteen patients (52%) were selected for induction of intensive cytotoxic treatment and complete remission was achieved only by some of these intensively treated patients (7 of 16). Of...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute myeloid leukemia; Elderly patients; G-banding karyotype; Induction therapy; Overall survival.
Ano: 2003 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000600004
Imagem não selecionada

Imprime registro no formato completo
Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome BJMBR
Pinheiro,R.F.; Serio,F.M.; Silva,M.R.R.; Briones,M.R.S.; Chauffaille,M.L.L.F..
Deletions on chromosomes 5 and 7 are frequently seen in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It is assumed that these deletions indicate loss of tumor suppressor genes on these chromosomes and until these tumor suppressor genes are identified, the functional consequences of these deletions and the molecular basis of these myeloid disorders cannot be completely understood. We evaluated loss of heterozygosity (LOH) in 44 patients (18 MDS and 26 AML, diagnosed according to WHO classification criteria) at diagnosis, using a four-microsatellite marker panel: an intragenic marker on the 7th intron of gene IRF-1 of the 5q31.1 region and three markers located inside the 7q31.1 region and correlated the LOH with karyotype abnormalities....
Tipo: Info:eu-repo/semantics/other Palavras-chave: Myelodysplastic syndrome; Acute myeloid leukemia; Cytogenetic abnormalities; Loss of heterozygosity.
Ano: 2008 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000700010
Imagem não selecionada

Imprime registro no formato completo
Atypical chromosome abnormalities in acute myeloid leukemia type M4 Genet. Mol. Biol.
Fett-Conte,Agnes C.; Estrela,Roseli Viscardi; Vendrame-Goloni,Cristina B.; Carvalho-Salles,Andréa B.; Ricci-Júnior,Octávio; Varella-Garcia,Marileila.
This study reports an adult AML-M4 patient with atypical chromosomal aberrations present in all dividing bone marrow cell at diagnosis: t(1;8)(p32.1;q24.2), der(9)t(9;10)(q22;?), and ins(19;9)(p13.3;q22q34) that may have originated transcripts with leukemogenic potential.
Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute myeloid leukemia; Chromosomal abnormalities; Chromosomal translocations.
Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572007000100002
Imagem não selecionada

Imprime registro no formato completo
Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades BJMBR
Souto Filho,J.T.; Portugal,R.D.; Loureiro,M.; Pulcheri,W.; Nucci,M..
We evaluated the outcome of 227 patients with acute myeloid leukemia during three decades (period 1 - 1980’s, N = 89; period 2 - 1990’s, N = 73; period 3 - 2000’s, N = 65) at a single institution. Major differences between the three groups included a higher median age, rates of multilineage dysplasia and co-morbidities, and a lower rate of clinical manifestations of advanced leukemia in recent years. The proportion of patients who received induction remission chemotherapy was 66, 75, and 85% for periods 1, 2, and 3, respectively (P = 0.04). The median survival was 40, 77, and 112 days, and the 5-year overall survival was 7, 13, and 22%, respectively (P = 0.01). The median disease-free survival was 266, 278, and 386 days (P = 0.049). Survival expectation...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute myeloid leukemia; Survival; Prognosis.
Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000700008
Imagem não selecionada

Imprime registro no formato completo
Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan Genet. Mol. Biol.
Mori,Naoki; Yoshinaga,Kentaro; Tada,Makiko; Wang,Yanhua; Shiseki,Masayuki; Motoji,Toshiko.
A unique mutation of the JAK2 gene, V617F, has recently been identified in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. To determine the relevance of this mutation in other types of hematological neoplasms in Japan, we performed allele-specific polymerase chain reaction analysis on the JAK2 gene. The V617F mutation was detected in one out of 130 myeloid neoplasms, but in none of 114 lymphoid malignancies and four biphenotypic acute leukemias. Although a favorable chromosomal alteration t(8;21)(q22;q22) was observed in one acute myeloid leukemia (AML) patient with the mutation, two courses of chemotherapy resulted in induction failure and short survival. Sequencing of JAK2 cDNA revealed expression of the mutant...
Tipo: Info:eu-repo/semantics/article Palavras-chave: JAK2 gene; V617F mutation; Signal transduction; Acute myeloid leukemia; Lymphoid malignancies.
Ano: 2008 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572008000300006
Imagem não selecionada

Imprime registro no formato completo
Levels of interleukins 12 (IL-12) and 13 (IL-13), hepatitis B and C serology, and blood cultures among acute myeloid leukemia (AML) patients in Egypt J. Venom. Anim. Toxins incl. Trop. Dis.
RAA,Nour el deen; RA,Harfoush; MM,Elgharabawy; NA,Hamed; MG,Morsi.
There is an interest in the use of IL-12 as a possible anti-cancer drug to induce immune responses and anti-IL-13 formulations to treat the undesirable effects of IL-13. Thus, the present study aimed at analyzing IL-12 and IL-13 profiles, viral hepatitis serology and blood cultures in acute myeloid leukemia (AML) patients. Forty individuals (20 without septicemia - Group A, and 20 with septicemia - Group B) and 20 healthy controls were evaluated. Hepatitis B virus antigens (HBsAg) and hepatitis C virus antibodies (HCV Ab) were quantified using commercial ELISA kits. IL-12 and IL-13 levels were estimated in culture supernatant of mitogen-stimulated peripheral blood mononuclear cells by ELISA. Significantly low IL-12 values were observed among AML patients...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute myeloid leukemia; IL-12; IL-13; HBsAg; HCV; ELISA.
Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992011000300009
Imagem não selecionada

Imprime registro no formato completo
Low expression of APAF-1XL in acute myeloid leukemia may be associated with the failure of remission induction therapy BJMBR
Benites,B.D.; Fattori,A.; Hackel,C.; Lorand-Metze,I.; De Souza,C.A.; Schulz,E.; Costa,F.F.; Saad,S.T.O..
Apoptotic protease activating factor 1 (APAF-1) has a critical role in the regulation of apoptosis. In the present study, the mRNA expression analysis of different APAF-1 transcripts (APAF-1S, APAF-1LC, APAF-1LN, and APAF-1XL) was analyzed in bone marrow samples from 37 patients with acute myeloid leukemia (newly diagnosed, with no previous treatment). APAF-1XL and APAF-1LN transcripts (with and without an extra WD-40 repeat region, respectively) were detected in all samples, although the major form expressed was APAF-1XL in 65% of the samples (group 1), while 35% of the samples expressed primarily APAF-1LN (group 2). Only 46% of the patients presented complete remission in response to remission induction therapy (represented by less than 5% marrow blasts...
Tipo: Info:eu-repo/semantics/article Palavras-chave: APAF-1; Acute myeloid leukemia; Apoptosis; Chemotherapy resistance.
Ano: 2008 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000700004
Imagem não selecionada

Imprime registro no formato completo
Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia BJMBR
Azevedo,M.C.; Velloso,E.D.R.P.; Buccheri,V.; Chamone,D.A.F.; Dorlhiac-Llacer,P.E..
In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 patients who received cytarabine consolidation were assigned to study groups by their cytarabine dose protocol. Group 1 (n=69) received <1.5 g/m2 every 12 h on 3...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute myeloid leukemia; Chemotherapy; Consolidation therapy; High-dose cytarabine; Prognosis.
Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200178
Imagem não selecionada

Imprime registro no formato completo
Secretory TAT-peptide-mediated protein transduction of LIF receptor α-chain distal cytoplasmic motifs into human myeloid HL-60 cells BJMBR
Sun,Q.; Xiong,J.; Lu,J.; Xu,S.; Li,Y.; Zhong,X.P.; Gao,G.K.; Liu,H.Q..
The distal cytoplasmic motifs of leukemia inhibitory factor receptor α-chain (LIFRα-CT3) can independently induce intracellular myeloid differentiation in acute myeloid leukemia (AML) cells by gene transfection; however, there are significant limitations in the potential clinical use of these motifs due to liposome-derived genetic modifications. To produce a potentially therapeutic LIFRα-CT3 with cell-permeable activity, we constructed a eukaryotic expression pcDNA3.0-TAT-CT3-cMyc plasmid with a signal peptide (ss) inserted into the N-terminal that codes for an ss-TAT-CT3-cMyc fusion protein. The stable transfection of Chinese hamster ovary (CHO) cells via this vector and subsequent selection by Geneticin resulted in cell lines that express and secrete...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Leukemia inhibitory factor; TAT-HIV1; Protein transduction domain; Acute myeloid leukemia; LIF receptor.
Ano: 2012 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012001000005
Imagem não selecionada

Imprime registro no formato completo
Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1'(R), 6'(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax ArchiMer
Florean, Cristina; Kim, Kyung Rok; Schnekenburger, Michael; Kim, Hyun-jung; Moriou, Celine; Debitus, Cecile; Dicato, Mario; Al-mourabit, Ali; Han, Byung Woo; Diederich, Marc.
Treatment of acute myeloid leukemia (AML) patients is still hindered by resistance and relapse, resulting in an overall poor survival rate. Recently, combining specific B-cell lymphoma (Bcl)-2 inhibitors with compounds downregulating myeloid cell leukemia (Mcl)-1 has been proposed as a new effective strategy to eradicate resistant AML cells. We show here that 1(R), 6(S), 1'(R), 6'(S), 11(R), 17(S)-fistularin-3, a bromotyrosine compound of the fistularin family, isolated from the marine sponge Suberea clavata, synergizes with Bcl-2 inhibitor ABT-199 to efficiently kill Mcl-1/Bcl-2-positive AML cell lines, associated with Mcl-1 downregulation and endoplasmic reticulum stress induction. The absolute configuration of carbons 11 and 17 of the fistularin-3...
Tipo: Text Palavras-chave: Acute myeloid leukemia; ABT-199; Mcl-1; Bromotyrosine; (+)-11(R); 17(S)-fistularin-3; Configuration; Anticancer drug combination.
Ano: 2018 URL: https://archimer.ifremer.fr/doc/00476/58783/62419.pdf
Registros recuperados: 12
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional